
Articles
-
Jan 21, 2025 |
ionanalytics.com | Rebecca Wenzel |Deborah Balshem |Dane Hamilton |Carlos Martinez
News (Intelligence) Timing not right for minority recapUnlikely to return to market soonConfluent Health, the Partners Group-backed musculoskeletal health company that was exploring a sale in 2024, ended the process late last year, said three sources familiar with the process.
-
Nov 5, 2024 |
ionanalytics.com | Rebecca Wenzel |Deborah Balshem |Carlos Martinez
News (Intelligence) Proceeds funded distribution to shareholders, doctor partners, and CharlesbankMB2 expects to generate USD 300m EBITDA this yearMB2 Dental, a dental services organization backed by Charlesbank Capital Partners, has pulled its sales process and pursued a dividend recapitalization, according to four sources familiar with the situation.
-
Sep 10, 2024 |
ionanalytics.com | Rebecca Wenzel |Deborah Balshem |Carlos Martinez
Three Oaks Hospice, a Dallas-based provider of hospice and palliative care services, is in the midst of a sale process, according to five sources familiar with the matter. The company is working alongside investment bank Harris Williams, according to four of the sources. The process is in the later stages and is down to a few private equity buyers, three of the sources said. Three Oaks generates between USD 12m and USD 15m EBITDA, according to all the sources. The business was founded in May 2019.
-
Aug 21, 2024 |
ionanalytics.com | Dane Hamilton |Deborah Balshem |Carlos Martinez
H2 Health, a Grant Avenue Capital-backed physical therapy provider, is exploring a sale via Jefferies, according to three sources familiar with the matter. The Jacksonville, Florida-based company is marketing itself off around USD 25m-USD 30m in EBITDA, the sources said. The process is in the early stages, with indications of interest collected this month, two of them added.
-
Aug 12, 2024 |
ionanalytics.com | Jeff Sheban |Rebecca Wenzel |Deborah Balshem |Izaz Ansari
Data Insight Revenue cycle management (RCM) has become one of the brightest stars in the healthcare technology firmament after the USD 7bn bid for R1 RCM [NASDAQ:RCM] from private-equity groups TowerBrook Capital Partners and Clayton, Dubilier & Rice on 1 August.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →